Furthermore, in an experimental liver fibrosis model, a dipeptidyl peptidase-4 inhibitor (DPP4-I), sitagliptin, attenuated liver fibrosis development along with the suppression of hepatic transforming growth factor (TGF)-β1, total collagen, and TIMP-1 levels in a dose-dependent manner [54]. Here, DPP4 is linked to Hepatic fibrosis.